Contract Research and Manufacturing Services (CRAMS) Market Report 2026

The contract research and manufacturing services (crams) market size has grown rapidly in recent years. It will grow from $155.61 billion in 2025 to $171.86 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising r&d costs in pharmaceutical sector, growing demand for innovative drugs, limited in-house manufacturing capabilities, increasing regulatory complexities, emergence of biotechnology companies.

The contract research and manufacturing services (crams) market size is expected to see rapid growth in the next few years. It will grow to $258.36 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing adoption of biologics and advanced therapies, expansion of clinical trial outsourcing, growing demand for personalized medicine, technological advancements in manufacturing automation, rising contract manufacturing for medical devices. Major trends in the forecast period include outsourcing of pharmaceutical r&d, expansion of biologics manufacturing services, increasing demand for analytical testing & quality control, growth in custom synthesis & production services, rising adoption of contract manufacturing for medical devices.

The growing ageing population with various chronic diseases is expected to positively influence the growth of the contract research and manufacturing services (CRAMS) market over the forecast period. The global ageing population is increasing rapidly and is projected to continue rising. As the geriatric population grows, the prevalence of diseases such as cancer, diabetes, Alzheimer’s, and arthritis is also expected to increase, driving demand for medicines and, consequently, contract research and manufacturing services. For example, in September 2023, the Australian Bureau of Statistics reported that Australia’s population, which was 26 million in 2022, is projected to reach between 34.3 million and 45.9 million by 2071. The median age, currently 38.5 years, is expected to rise to between 43.8 and 47.6 years. Therefore, the increasing ageing population is set to drive growth in the CRAMS market.

Artificial intelligence (AI) is increasingly being leveraged in the CRAMS market to strengthen market positioning. AI, a branch of computer science, focuses on simulating human behavior in machines. It helps optimize operations by predicting maintenance needs and supporting healthcare systems. For instance, in June 2024, Medidata, a US-based technology company, launched the Medidata Clinical Data Studio, which integrates and manages clinical trial data from multiple sources to improve research efficiency and accuracy. The platform uses AI to streamline data review and reconciliation, enabling study teams to detect potential data issues and safety signals more effectively. It offers a comprehensive workspace for data integration, transformation, and management, supporting risk-based quality management strategies and providing real-time insights.

In October 2023, Sterling Pharma Solutions, a UK-based contract development and manufacturing organization, acquired NewChem Technologies Ltd. for an undisclosed amount. The acquisition aims to expand Sterling Pharma Solutions’ capacity to address complex process chemistry challenges and establish itself as a preferred partner for small molecule services in the pharmaceutical industry. NewChem Technologies Ltd. is a UK-based contract research organization.

Major companies operating in the contract research and manufacturing services (crams) market are Lonza Group, Catalent Inc., WuXi AppTec, Boehringer Ingelheim, Charles River Laboratories, Jubilant Life Sciences, PRA Health Sciences, Syngene International Ltd., Samsung Biologics, Evotec AG, AMRI (Albany Molecular Research Inc.), Parexel International Corporation, ICON plc, IQVIA Holdings Inc., PPD (Pharmaceutical Product Development), Recipharm AB, Curia Global Inc., Cambrex Corporation, Labcorp Drug Development, CordenPharma, Medpace Holdings Inc., FAMAR Health Care Services, Rentschler Biopharma SE, PCI Pharma Services, Dishman Carbogen Amcis Ltd., Thermo Fisher Scientific Inc., ProPharma Group, Siegfried AG.

North America was the largest region in the contract research and manufacturing services (CRAMS) market in 2025. Asia-Pacific region is expected to grow at a faster pace in the forecast period. The regions covered in the contract research and manufacturing services (crams) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the contract research and manufacturing services (crams) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the CRAMS market by increasing costs for imported raw materials, APIs, and specialized manufacturing equipment, disrupting global supply chains. The manufacturing and research segments, especially in North America and Asia-Pacific regions like India and China, are most affected due to their dependency on imported intermediates and lab equipment. While tariffs have increased operational costs, they also encourage local production investments and diversification of sourcing strategies, leading to more resilient and cost-efficient contract research and manufacturing operations.

The contract research and manufacturing services (crams) market research report is one of a series of new reports that provides contract research and manufacturing services (crams) market statistics, including contract research and manufacturing services (crams) industry global market size, regional shares, competitors with a contract research and manufacturing services (crams) market share, detailed contract research and manufacturing services (crams) market segments, market trends and opportunities, and any further data you may need to thrive in the contract research and manufacturing services (crams) industry. This contract research and manufacturing services (crams) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Contract research and manufacturing services (CRAMS) refer to the practice of outsourcing product development and research tasks to companies that can perform them at a cost-effective price. In this model, the parent company does not directly manufacture the product itself.

The main types of services provided by CRAMS are manufacturing and research. Manufacturing services involve outsourcing drug development to pharmaceutical or biotechnology companies under contract. Contract manufacturing organizations (CMOs) participate in the entire development process, from clinical trials through all phases to the commercialization of drugs. Research services include outsourcing activities such as clinical trial data management, database design and construction, data entry and validation, medical and disease coding, project management, quality and metric reporting, safety and efficacy summaries, and statistical analysis plans and reports, all on a contract basis. CRAMS are utilized by pharmaceutical and biotechnology companies, medical device manufacturers, and academic institutions.

The contract research and manufacturing services (CRAMS) market includes revenues earned by entities by minimizing cost and focusing on more functional areas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.